Compare Heron Therapeutics Inc (HRTX) vs Union Pacific Corporation (UNP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Union Pacific Corporation — how do they compare? Heron Therapeutics Inc trades at $0.46 (market cap $91.46M), while Union Pacific Corporation trades at $294.46 (market cap $175.89B). The key difference: Union Pacific Corporation is far larger — about 1923.1× Heron Therapeutics Inc's market cap, and Union Pacific Corporation pays a 1.86% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HRTX | UNP | |
|---|---|---|
Market Cap | $91.46M | $175.89B |
Sector | Health | Industrials |
52-Week High | $1.96 | $301.75 |
52-Week Low | $0.39 | $214.91 |
Enterprise Value | $189.36M | $206.36B |
Dividend Yield | — | 1.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.
Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.
Union Pacific (UNP) trades at $296.00, down 1.91% amid mixed technical signals. The stock shows strong fundamentals with 29.2% net margins and 40.69% ROE, while Q1 2026 earnings beat expectations. Analysts maintain a bullish consensus with a $311.07 price target. Recent news highlights the Norfolk Southern merger progress and upcoming Q2 earnings, with institutional buying supporting positive sentiment despite regulatory and legal overhangs.
Outlook remains positive given earnings momentum and operational efficiency, but risks include merger regulatory scrutiny, pending class action litigation, and cyclical freight demand. The stock offers value near consensus targets with dividend growth, though investors should weigh execution risks against solid profitability trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Union Pacific Corporation
Omaha, Nebraska-based Union Pacific is the largest public railroad in North America. Operating on more than 30,000 miles of track in the western two thirds of the U.S., UP generated roughly $22 billion of revenue in 2021 by hauling coal, industrial products, intermodal containers, agriculture goods, chemicals, and automotive goods. UP owns about one fourth of Mexican railroad Ferromex and derives about 10% of its revenue hauling freight to and from Mexico.
Read more on UNP →
